$11.41
0.62% yesterday
Nasdaq, Nov 18, 10:00 pm CET
ISIN
CA60255C1095
Symbol
MNMD

Mind Medicine Inc - Ordinary Shares (Sub Voting) Stock price

$11.41
-1.75 13.30% 1M
+4.40 62.77% 6M
+4.45 63.94% YTD
+4.57 66.81% 1Y
+8.70 321.03% 3Y
-5.54 32.68% 5Y
-15.53 57.65% 10Y
-15.53 57.65% 20Y
Nasdaq, Closing price Tue, Nov 18 2025
+0.07 0.62%
ISIN
CA60255C1095
Symbol
MNMD
Industry

New AI Insights on Mind Medicine Inc - Ordinary Shares (Sub Voting) Insights AI Insights on Mind Medicine Inc - Ordinary Shares (Sub Voting)

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$1.1b
Enterprise Value
$948.4m
Net debt
positive
Cash
$209.1m
Shares outstanding
76.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
8.6
Financial Health
Equity Ratio
79.9%
Return on Equity
-45.0%
ROCE
-88.2%
ROIC
-
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-151.2m | $-154.5m
EBIT
$-151.2m | $-162.0m
Net Income
$-168.1m | $-139.1m
Free Cash Flow
$-113.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-63.7% | -49.4%
EBIT
-61.4% | -55.9%
Net Income
-71.9% | -28.0%
Free Cash Flow
-53.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.0
FCF per Share
$-1.5
Short interest
12.1%
Employees
74
Rev per Employee
$0.0
Show more

Is Mind Medicine Inc - Ordinary Shares (Sub Voting) a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.

Mind Medicine Inc - Ordinary Shares (Sub Voting) Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Mind Medicine Inc - Ordinary Shares (Sub Voting) forecast:

17x Buy
94%
1x Hold
6%

Analyst Opinions

18 Analysts have issued a Mind Medicine Inc - Ordinary Shares (Sub Voting) forecast:

Buy
94%
Hold
6%

Financial data from Mind Medicine Inc - Ordinary Shares (Sub Voting)

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 46 46
19% 19%
-
- Research and Development Expense 105 105
96% 96%
-
-151 -151
64% 64%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -151 -151
61% 61%
-
Net Profit -168 -168
72% 72%
-

In millions USD.

Don't miss a Thing! We will send you all news about Mind Medicine Inc - Ordinary Shares (Sub Voting) directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mind Medicine Inc - Ordinary Shares (Sub Voting) Stock News

Neutral
Seeking Alpha
12 days ago
Mind Medicine (MindMed) Inc. ( MNMD ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Robert Barrow - CEO & Director Daniel Karlin - Chief Medical Officer Brandi Roberts - Chief Financial Officer Conference Call Participants Yesha Patel - Evercore ISI Institutional Equities, Research Division Sarah Medeiros - Cantor Fitzgerald & Co., Research Division Matthew Hershenhorn...
Neutral
Business Wire
12 days ago
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported financial results for the third quarter ended September 30, 2025 and provided business updates. “2025 continues to be a year of strong execution, and our recent $2...
Neutral
Business Wire
14 days ago
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will participate in the following investor conferences: Stifel 2025 Healthcare Conference Format: Presentation Date a...
More Mind Medicine Inc - Ordinary Shares (Sub Voting) News

Company Profile

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn in 2019 and is headquarter in New York, NY.

Head office Canada
CEO Robert Barrow
Employees 74
Founded 2019
Website ir.mindmed.co

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today